Jubilant Pharmova’s Q3 Earnings Driven By Covid-19 Led Opportunities: Prabhudas Lilladher
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
Jubilant Pharmova Ltd.’s Q3 FY21 earnings were driven by Covid-19 led contract development and manufacturing organisation (vaccine and active pharmaceutical ingredient to Gilead) and generics segment (Remdesivir formulation) and it guided that the opportunities would continue for next 18-24 months.
The company and Ingrevia has also reduced their net debt ahead of guidance to Rs 20 billion and Rs 5 billion versus earlier guidance of Rs 22 billion and Rs 9 billion.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.